What does Lukas Biomedical Inc. do?

Lukas Biomedical Inc. (6814.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6814.TWO's market cap?

Lukas Biomedical Inc. (6814.TWO) has a market capitalization of approximately $833.3 million, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6814.TWO pay a dividend?

No — Lukas Biomedical Inc. (6814.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6814.TWO profitable?

Lukas Biomedical Inc. (6814.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6814.TWO

Lukas Biomedical Inc.

TWO·Biotechnology · Healthcare

NT$19.90NT$1.60−7.44%

Market capNT$833.29M·Aug 26 6:23 AM UTC

Price Chart

NT$19.90−NT$1.60 (−7.44%)today

−57.71%CAGR −15.82%

Select date range

FromTo

Dec 31, 2020Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6814.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$170.01M

Net Income−NT$92.05M

Net Margin−54.1%

Operating Cash Flow−NT$66.75M

Capital ExpendituresNT$1.11M

Free Cash Flow−NT$67.87M

Return on Equity−48.1%

Return on Invested Capital−10.6%

Net DebtNT$221.94M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6814.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6814.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6814.TWO and 80,000+ other tickers.

About Lukas Biomedical Inc.

Founded in 2002 and headquartered in New Taipei, Taiwan, Lukas Biomedical Inc. primarily develops immune cell medical technologies. These innovations are utilized for regenerative medicine and as complementary treatments for cancer. The company's operations are segmented into four distinct areas: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. Furthermore, it diversifies its business by wholesaling and retailing cosmetics, alongside providing housing equipment rental services.

CEO: Chaoan Liu
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 87
Website: www.lukas-biomedical.com

Peers

Peers Tab

6810.TWO

Bio Preventive Medicine Corp.

Cap

NT$1.1B

7725.TWO

LabTurbo Biotech Corporation

Cap

NT$1.1B

6876.TWO

LAUNXP Biomedical Co., Ltd

Cap

NT$834.1M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6814.TWO

What does Lukas Biomedical Inc. do?: Lukas Biomedical Inc. (6814.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6814.TWO's market cap?: Lukas Biomedical Inc. (6814.TWO) has a market capitalization of approximately $833.3 million, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6814.TWO pay a dividend?: No — Lukas Biomedical Inc. (6814.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6814.TWO profitable?: Lukas Biomedical Inc. (6814.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.